# STELLAR-303 (NCT05425940)

> Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05425940
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Exelixis
- Conditions: Colorectal Cancer
- Interventions: XL092; Atezolizumab; Regorafenib
- Enrollment: 901
- Primary outcome: Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized Participants
- Primary outcome: Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in Randomized Non-Liver Metastases (NLM) Participants

## Commentary we found

- X threads: 43
- YouTube: 31
- Podcasts: 15
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=stellar-303-nct05425940

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05425940", "email": "<work email>"}; the inbox owner confirms by the emailed link.